|
JPS5852225A
(ja)
*
|
1981-09-22 |
1983-03-28 |
Mitsui Pharmaceut Inc |
脱髄疾患治療剤
|
|
US5766920A
(en)
*
|
1982-08-11 |
1998-06-16 |
Cellcor, Inc. |
Ex vivo activation of immune cells
|
|
US4550086A
(en)
*
|
1983-02-16 |
1985-10-29 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that recognize human T cells
|
|
IL69686A
(en)
*
|
1983-09-11 |
1988-03-31 |
Yeda Res & Dev |
Compositions containing cell membrane proteins and process for their preparation
|
|
US4608365A
(en)
*
|
1984-03-30 |
1986-08-26 |
University Of Southern California |
Treatment of neurologic functions
|
|
US4677061A
(en)
*
|
1984-10-19 |
1987-06-30 |
Genetic Systems Corporation |
T-cell lymphocyte subset monitoring of immunologic disease
|
|
US4902680A
(en)
*
|
1984-10-29 |
1990-02-20 |
Chaovanee Aroonsakul |
Treating central nervous system diseases
|
|
US4898857A
(en)
*
|
1984-10-29 |
1990-02-06 |
Chaovanee Aroonsakul |
Treating control nervous system diseases
|
|
US4898856A
(en)
*
|
1984-10-29 |
1990-02-06 |
Chaovanee Aroonsakul |
Method for treating central nervous system diseases
|
|
US4897389A
(en)
*
|
1984-10-29 |
1990-01-30 |
Chaovanee Aroonsakul |
Treating central nervous system diseases
|
|
CA1296622C
(en)
*
|
1986-08-12 |
1992-03-03 |
Jeffrey E. Anderson |
Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
|
|
US5849298A
(en)
*
|
1987-06-24 |
1998-12-15 |
Autoimmune Inc. |
Treatment of multiple sclerosis by oral administration of bovine myelin
|
|
US5039660A
(en)
*
|
1988-03-02 |
1991-08-13 |
Endocon, Inc. |
Partially fused peptide pellet
|
|
US5242687A
(en)
*
|
1989-03-15 |
1993-09-07 |
Tkb Associates Limited Partnership |
Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
|
|
US6207645B1
(en)
*
|
1989-03-21 |
2001-03-27 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
|
|
US5861164A
(en)
*
|
1989-03-21 |
1999-01-19 |
The Immune Response Corporation |
Vaccination against diseases resulting from pathogenic responses by specific T cell populations
|
|
US5612035A
(en)
*
|
1989-03-21 |
1997-03-18 |
The Immune Response Corporation |
Vaccination against diseases resulting from pathogenic responses by specific T cell populations
|
|
US6221352B1
(en)
*
|
1989-03-21 |
2001-04-24 |
The Immune Response Corporation |
Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
|
|
US6007815A
(en)
*
|
1989-03-21 |
1999-12-28 |
The Immune Response Corporation |
Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
|
|
US5837246A
(en)
*
|
1989-03-21 |
1998-11-17 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
|
|
US5776459A
(en)
*
|
1989-07-19 |
1998-07-07 |
Connetics Corporation |
TCR V beta 5 peptides
|
|
US5614192A
(en)
*
|
1989-07-19 |
1997-03-25 |
Connective Therapeutics, Inc. |
T cell receptor peptides as therapeutics for immune-related disease
|
|
US5298396A
(en)
*
|
1989-11-15 |
1994-03-29 |
National Jewish Center For Immunology And Respiratory Medicine |
Method for identifying T cells disease involved in autoimmune disease
|
|
AU8407091A
(en)
*
|
1990-07-06 |
1992-02-04 |
Allergene, Inc. |
Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
|
|
US5668117A
(en)
*
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
|
US5211952A
(en)
*
|
1991-04-12 |
1993-05-18 |
University Of Southern California |
Contraceptive methods and formulations for use therein
|
|
US6083503A
(en)
*
|
1991-08-28 |
2000-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
|
|
US5480895A
(en)
*
|
1991-09-27 |
1996-01-02 |
New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery |
Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
|
|
US5545716A
(en)
*
|
1992-09-08 |
1996-08-13 |
University Of Florida |
Superantigen agonist and antagonist peptides
|
|
WO1994020120A1
(en)
*
|
1993-03-12 |
1994-09-15 |
Cellcor, Inc. |
In vitro assay measuring degree of activation of immune cells
|
|
WO1994022451A1
(en)
*
|
1993-04-07 |
1994-10-13 |
Oklahoma Medical Research Foundation |
Selective regulation of b lymphocyte precursors by hormones
|
|
IL110787A0
(en)
*
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
|
JPH09510437A
(ja)
*
|
1993-12-28 |
1997-10-21 |
カイロン ミモトープス プロプライエトリー リミテッド |
Ｔ細胞エピトープ
|
|
US5552300A
(en)
*
|
1994-01-13 |
1996-09-03 |
T Cell Sciences, Inc. |
T cell antigen receptor V region proteins and methods of preparation thereof
|
|
US6410518B1
(en)
*
|
1994-05-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US5674487A
(en)
*
|
1994-09-28 |
1997-10-07 |
Univ Jefferson |
Method for treating autoimmune diseases
|
|
US5723503A
(en)
*
|
1994-09-28 |
1998-03-03 |
Thomas Jefferson University |
Biological treatment for rheumatoid arthritis
|
|
US6033661A
(en)
*
|
1995-06-07 |
2000-03-07 |
Thomas Jefferson University |
Composition and method for allogenetic mononuclear cell immunotherapy
|
|
US6096314A
(en)
*
|
1994-10-07 |
2000-08-01 |
Yeda Research And Development Co. Ltd. |
Peptides and pharmaceutical compositions comprising them
|
|
FR2727117A1
(fr)
*
|
1994-11-18 |
1996-05-24 |
Geffard Michel |
Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
|
|
DE69525544T2
(de)
*
|
1994-11-18 |
2002-08-22 |
Neurocrine Biosciences, Inc. |
Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
|
|
US6218166B1
(en)
*
|
1994-12-09 |
2001-04-17 |
John Wayne Cancer Institute |
Adjuvant incorporation into antigen carrying cells: compositions and methods
|
|
US5874531A
(en)
*
|
1995-03-07 |
1999-02-23 |
President And Fellows Of Harvard College |
Identification of self and non-self antigens implicated autoimmune disease
|
|
US5869057A
(en)
*
|
1995-06-07 |
1999-02-09 |
Rock; Edwin P. |
Recombinant vaccines to break self-tolerance
|
|
SE9502921D0
(sv)
*
|
1995-08-23 |
1995-08-23 |
Astra Ab |
New compounds
|
|
US5739307A
(en)
*
|
1995-08-28 |
1998-04-14 |
Washington University |
Polynucleotide encoding neurturin neurotrophic factor
|
|
US5716946A
(en)
*
|
1996-02-13 |
1998-02-10 |
Wisconsin Alumni Research Foundation |
Multiple sclerosis treatment
|
|
US5750356A
(en)
*
|
1996-05-31 |
1998-05-12 |
Anergen, Inc. |
Method for monitoring T cell reactivity
|
|
US5849886A
(en)
*
|
1996-07-10 |
1998-12-15 |
Oy Aboatech Ab |
Extraction of myelin basic protein
|
|
US20010031253A1
(en)
*
|
1996-07-24 |
2001-10-18 |
Gruenberg Micheal L. |
Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
|
|
US6130087A
(en)
*
|
1996-10-07 |
2000-10-10 |
Fordham University |
Methods for generating cytotoxic T cells in vitro
|
|
CN1237909A
(zh)
*
|
1996-10-11 |
1999-12-08 |
加利福尼亚大学董事会 |
联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗
|
|
US6054292A
(en)
*
|
1997-07-18 |
2000-04-25 |
Incyte Pharmaceuticals, Inc. |
T-cell receptor protein
|
|
US20020009448A1
(en)
*
|
1997-09-19 |
2002-01-24 |
Leslie P. Weiner |
T-cell vaccination for the treatment of multiple sclerosis
|
|
US20020072493A1
(en)
*
|
1998-05-19 |
2002-06-13 |
Yeda Research And Development Co. Ltd. |
Activated T cells, nervous system-specific antigens and their uses
|
|
US20020001841A1
(en)
*
|
1998-06-26 |
2002-01-03 |
Keld Kaltoft |
Continuous t-cell lines
|
|
CA2362099C
(en)
*
|
1999-02-23 |
2014-05-13 |
Baylor College Of Medicine |
T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection
|
|
US6187750B1
(en)
*
|
1999-08-25 |
2001-02-13 |
Everyoung Technologies, Inc. |
Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
|
|
US6746670B2
(en)
*
|
2000-08-15 |
2004-06-08 |
Schering Corporation |
Regulatory T cells; methods
|
|
SI1731912T1
(sl)
*
|
2000-08-21 |
2014-05-30 |
Apitope Technology (Bristol) Limited |
Postopek izbire peptida
|
|
AU2001297741A1
(en)
*
|
2000-11-22 |
2002-10-08 |
Diadexus, Inc. |
Compositions and methods relating to breast specific genes and proteins
|
|
US20030078347A1
(en)
*
|
2001-08-28 |
2003-04-24 |
General Electric Company |
Triazine compounds, polymers comprising triazine structural units, and method
|
|
US7658926B2
(en)
*
|
2001-09-14 |
2010-02-09 |
Opexa Pharmaceuticals, Inc. |
Autologous T-cell vaccines materials and methods
|
|
EP1444330A1
(en)
*
|
2001-11-07 |
2004-08-11 |
Kirin Beer Kabushiki Kaisha |
Expansion of t cells in vitro and expanded t cell populations
|
|
US20050181459A1
(en)
*
|
2002-06-11 |
2005-08-18 |
Matthew Baker |
Method for mapping and eliminating T cell epitopes
|
|
EP1677821B1
(en)
*
|
2003-10-17 |
2013-02-27 |
Baylor College Of Medicine |
A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis
|
|
BRPI0415816A
(pt)
*
|
2003-10-31 |
2006-12-26 |
Univ British Columbia |
composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit
|
|
US20090214580A1
(en)
*
|
2004-02-02 |
2009-08-27 |
Houghten Richard A |
Peptide mixtures with immunomodulatory activity
|